Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 13 04:00PM ET
0.3670
Dollar change
-0.0030
Percentage change
-0.81
%
Index- P/E- EPS (ttm)-2.87 Insider Own16.58% Shs Outstand30.17M Perf Week-19.78%
Market Cap10.98M Forward P/E- EPS next Y-1.15 Insider Trans4.85% Shs Float25.17M Perf Month-88.57%
Income-86.49M PEG- EPS next Q-0.71 Inst Own41.26% Short Float4.21% Perf Quarter-87.89%
Sales0.00M P/S- EPS this Y16.46% Inst Trans-8.53% Short Ratio1.42 Perf Half Y-87.81%
Book/sh1.58 P/B0.23 EPS next Y58.15% ROA-104.91% Short Interest1.06M Perf Year-85.32%
Cash/sh1.81 P/C0.20 EPS next 5Y- ROE-116.60% 52W Range0.36 - 7.22 Perf YTD-91.14%
Dividend Est.- P/FCF- EPS past 5Y-2.94% ROI-181.60% 52W High-94.92% Beta0.38
Dividend TTM- Quick Ratio6.89 Sales past 5Y0.00% Gross Margin- 52W Low2.60% ATR (14)0.26
Dividend Ex-Date- Current Ratio6.89 EPS Y/Y TTM22.59% Oper. Margin- RSI (14)16.00 Volatility10.40% 11.82%
Employees20 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom3.00 Target Price0.87
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q1.50% Payout- Rel Volume1.16 Prev Close0.37
Sales Surprise- EPS Surprise-6.67% Sales Q/Q- EarningsNov 07 AMC Avg Volume747.39K Price0.37
SMA20-80.94% SMA50-87.06% SMA200-89.46% Trades Volume864,457 Change-0.81%
Date Action Analyst Rating Change Price Target Change
Dec-05-24Downgrade Mizuho Outperform → Neutral $23 → $1
Sep-17-24Upgrade Jefferies Hold → Buy $3.50 → $13
Jun-05-24Downgrade Goldman Neutral → Sell $3 → $2
Oct-14-22Downgrade Truist Buy → Hold $90 → $10
Oct-14-22Downgrade Guggenheim Buy → Neutral
Oct-14-22Downgrade Goldman Buy → Neutral $81 → $8
Oct-13-22Downgrade Oppenheimer Outperform → Perform $64 → $7
Nov-18-21Initiated Mizuho Buy $50
May-20-21Resumed Goldman Buy $78
Oct-28-20Downgrade Goldman Buy → Neutral $69 → $40
Dec-09-24 07:30AM
Dec-05-24 07:36AM
Dec-04-24 07:30AM
Nov-19-24 09:00AM
Nov-14-24 07:30AM
09:02PM Loading…
Nov-10-24 09:02PM
Nov-08-24 02:28AM
Nov-07-24 04:32PM
Nov-04-24 04:30PM
Sep-12-24 01:07AM
01:06AM
Aug-12-24 09:35AM
Aug-08-24 01:51PM
Aug-07-24 04:05PM
Aug-05-24 07:30AM
08:30AM Loading…
Jun-18-24 08:30AM
Jun-10-24 07:30AM
Jun-03-24 07:30AM
May-28-24 06:10AM
May-11-24 08:41AM
May-09-24 06:20AM
03:40AM
May-08-24 09:55PM
04:05PM
May-06-24 07:30AM
Mar-20-24 10:27AM
06:27AM
Mar-19-24 08:52PM
05:31PM
04:15PM
07:30AM Loading…
Mar-12-24 07:30AM
Mar-05-24 07:30AM
Feb-01-24 03:02PM
Jan-05-24 05:12PM
Jan-04-24 07:30AM
Dec-29-23 08:47AM
Dec-20-23 02:39PM
02:14PM
Nov-10-23 01:57PM
Nov-08-23 06:47PM
04:01PM
Nov-03-23 07:30AM
Oct-11-23 08:31AM
Oct-09-23 07:30AM
Oct-06-23 07:30AM
Sep-20-23 08:30AM
Aug-23-23 07:30AM
Aug-08-23 04:01PM
Aug-01-23 07:30AM
Jul-31-23 06:10AM
Jun-08-23 07:30AM
Jun-02-23 07:30AM
May-24-23 07:42AM
07:30AM
May-11-23 04:01PM
May-08-23 07:30AM
Apr-12-23 12:59PM
Mar-27-23 07:12AM
Mar-24-23 09:08AM
Mar-23-23 04:01PM
Mar-17-23 08:30AM
Feb-27-23 09:13AM
Feb-17-23 06:35AM
Jan-12-23 08:00AM
Jan-09-23 08:00AM
Dec-29-22 09:11AM
Dec-15-22 06:08AM
Dec-08-22 08:39AM
08:12AM
Dec-07-22 04:05PM
Nov-10-22 04:05PM
Nov-08-22 04:15PM
Nov-03-22 12:24PM
Oct-20-22 11:28AM
Oct-14-22 12:55PM
11:30AM
Oct-13-22 04:04PM
08:49AM
08:00AM
07:00AM
Sep-20-22 08:30AM
Aug-14-22 10:14AM
Aug-11-22 04:15PM
Aug-09-22 08:30AM
Aug-05-22 08:30AM
Jul-21-22 08:30AM
Jul-04-22 06:51AM
Jun-07-22 08:30AM
Jun-02-22 08:30AM
May-25-22 08:30AM
May-10-22 12:25PM
May-05-22 04:01PM
Apr-29-22 08:30AM
Apr-28-22 09:00AM
Apr-04-22 09:00AM
Mar-23-22 04:05PM
Mar-16-22 08:30AM
Mar-10-22 08:30AM
Mar-09-22 01:24AM
Mar-08-22 04:00PM
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TRAVERSA SERGIOChief Executive OfficerSep 11 '24Buy2.9951,407153,707384,024Sep 11 05:47 PM
TRAVERSA SERGIOChief Executive OfficerSep 09 '24Buy2.7155,579150,619299,603Sep 11 05:47 PM
TRAVERSA SERGIOChief Executive OfficerSep 10 '24Buy2.7533,01490,788332,617Sep 11 05:47 PM
CASAMENTO CHARLES JDirectorSep 09 '24Buy2.5613,00033,28013,000Sep 11 05:47 PM
Shenouda MagedChief Financial OfficerSep 11 '24Buy2.9524,12071,15488,335Sep 11 05:46 PM
Shenouda MagedChief Financial OfficerSep 10 '24Buy2.7321,11857,65264,215Sep 11 05:46 PM
Shenouda MagedChief Financial OfficerSep 09 '24Buy2.558,19420,89543,097Sep 11 05:46 PM
Kelly Paul EdwardDirectorSep 09 '24Buy2.5925,00064,750212,295Sep 11 05:46 PM
TRAVERSA SERGIOChief Executive OfficerJan 30 '24Buy3.9040,999159,949216,564Jan 31 06:29 PM
TRAVERSA SERGIOChief Executive OfficerJan 29 '24Buy3.7131,541117,036175,565Jan 31 06:29 PM
TRAVERSA SERGIOChief Executive OfficerJan 31 '24Buy4.0027,460109,752244,024Jan 31 06:29 PM
Shenouda MagedChief Financial OfficerJan 30 '24Buy3.8915,00058,32328,028Jan 31 06:28 PM
Shenouda MagedChief Financial OfficerJan 29 '24Buy3.6510,80039,45013,028Jan 31 06:28 PM
Shenouda MagedChief Financial OfficerJan 31 '24Buy4.066,87527,94334,903Jan 31 06:28 PM
Ence ChuckCA and COJan 30 '24Buy3.8714,50056,05325,300Jan 31 06:28 PM
Ence ChuckCA and COJan 31 '24Buy4.0513,67055,42938,970Jan 31 06:28 PM
Ence ChuckCA and COJan 29 '24Buy3.6510,80039,43810,800Jan 31 06:28 PM